Fournier A - Search Results

1

Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity.

Nguyen TT, Folch B, Létourneau M, Truong NH, Doucet N, Fournier A, Chatenet D. Nguyen TT, et al. Among authors: fournier a. J Med Chem. 2014 Mar 27;57(6):2623-33. doi: 10.1021/jm401904q. Epub 2014 Mar 4. J Med Chem. 2014. PMID: 24552570

2

Cardiotoxin-I: an unexpectedly potent insulinotropic agent.

Nguyen TT, Folch B, Létourneau M, Vaudry D, Truong NH, Doucet N, Chatenet D, Fournier A. Nguyen TT, et al. Among authors: fournier a. Chembiochem. 2012 Aug 13;13(12):1805-12. doi: 10.1002/cbic.201200081. Epub 2012 Jul 16. Chembiochem. 2012. PMID: 22807058

3

Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

Chatenet D, Folch B, Feytens D, Létourneau M, Tourwé D, Doucet N, Fournier A. Chatenet D, et al. Among authors: fournier a. J Med Chem. 2013 Dec 12;56(23):9612-22. doi: 10.1021/jm401153j. Epub 2013 Nov 26. J Med Chem. 2013. PMID: 24251366

4

Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in a structure-activity relationship study of a class B GPCR ligand.

Doan ND, Poujol de Molliens M, Létourneau M, Fournier A, Chatenet D. Doan ND, et al. Among authors: fournier a. Eur J Med Chem. 2015 Nov 2;104:106-14. doi: 10.1016/j.ejmech.2015.09.017. Epub 2015 Sep 21. Eur J Med Chem. 2015. PMID: 26448038

5

Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects.

Doan ND, Bourgault S, Dejda A, Létourneau M, Detheux M, Vaudry D, Vaudry H, Chatenet D, Fournier A. Doan ND, et al. Among authors: fournier a. Biochem Pharmacol. 2011 Feb 15;81(4):552-61. doi: 10.1016/j.bcp.2010.11.015. Epub 2010 Nov 27. Biochem Pharmacol. 2011. PMID: 21114961

6

Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

Chatenet D, Nguyen QT, Létourneau M, Dupuis J, Fournier A. Chatenet D, et al. Among authors: fournier a. Biochem Pharmacol. 2012 Mar 1;83(5):608-15. doi: 10.1016/j.bcp.2011.12.009. Epub 2011 Dec 16. Biochem Pharmacol. 2012. PMID: 22197588

7

Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide.

Doan ND, Létourneau M, Vaudry D, Doucet N, Folch B, Vaudry H, Fournier A, Chatenet D. Doan ND, et al. Among authors: fournier a. J Control Release. 2012 Oct 28;163(2):256-65. doi: 10.1016/j.jconrel.2012.08.021. Epub 2012 Aug 24. J Control Release. 2012. PMID: 22922050

8

Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Chatenet D, Nguyen TT, Létourneau M, Fournier A. Chatenet D, et al. Among authors: fournier a. Front Endocrinol (Lausanne). 2013 Jan 2;3:174. doi: 10.3389/fendo.2012.00174. eCollection 2012. Front Endocrinol (Lausanne). 2013. PMID: 23293631 Free PMC article.

9

Design and application of light-activated probes for cellular signaling.

Chatenet D, Bourgault S, Fournier A. Chatenet D, et al. Among authors: fournier a. Methods Mol Biol. 2015;1234:17-30. doi: 10.1007/978-1-4939-1755-6_3. Methods Mol Biol. 2015. PMID: 25304345

10

Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands.

Nassour H, Hoang TA, Martin RD, Dallagnol JCC, Billard É, Létourneau M, Novellino E, Carotenuto A, Allen BG, Tanny JC, Fournier A, Hébert TE, Chatenet D. Nassour H, et al. Among authors: fournier a. J Biol Chem. 2021 Sep;297(3):101057. doi: 10.1016/j.jbc.2021.101057. Epub 2021 Aug 10. J Biol Chem. 2021. PMID: 34389356 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,969 results

Search Page

Filters